The program shifts the paradigm from population-based screening to individualized risk assessment. By integrating whole genome sequencing, clinical history, and machine learning, the company’s Stage Alpha Operating System monitors what it terms Oncologic Biological Drift—the evolution of a patient's risk profile over time. This approach allows oncologists to assist primary care physicians in determining precisely which screening tests are necessary and when they should be performed.

Co-founders Jose Barreau, MD, and Amit Gupta, MD, argue that current protocols rely too heavily on age-based averages rather than unique biological markers. Their model utilizes approximately 3.1 million de-identified patient records to refine its predictive capabilities. Rather than providing static testing, the service offers a continuous, oncologist-led review process designed to identify disease at the earliest actionable point. The program is currently available through concierge and direct primary care practices in Florida, with plans to expand nationally.